Sign In

Sean McClain

Founder & CEO at AbSci

Sean McClain is the founder and CEO of AbSci, a pioneering biotechnology company that leverages AI and synthetic biology to revolutionize protein-based drug development. He founded AbSci in 2011 at the age of 22, shortly after graduating from the University of Arizona with a degree in Biochemistry and Molecular Biology.14

Under McClain's leadership, AbSci has grown significantly, achieving a valuation nearing $2 billion and employing over 200 people.14 The company is headquartered in Vancouver, Washington, and focuses on developing scalable protein production technologies, including its SoluPro platform, which accelerates drug discovery timelines and reduces manufacturing costs.25

McClain has received several awards for his entrepreneurial achievements, including being named an Entrepreneur Of The Year 2020 Pacific Northwest Region Award winner and being featured in Forbes' 30 Under 30 list.36 His LinkedIn profile can be found under the username sean-mcclain.6

Key Achievements and Roles:

  • Founder & CEO of AbSci: Since August 2011, McClain has led AbSci in pioneering AI-driven drug discovery and synthetic biology.16
  • Education: Graduated from the University of Arizona with a degree in Biochemistry and Molecular Biology.14
  • Awards: Recognized as an Entrepreneur Of The Year and featured in Forbes' 30 Under 30.36
  • Company Growth: Led AbSci to a valuation nearing $2 billion and expanded its workforce significantly.14

Highlights

Jan 10 · linkedin

I’m incredibly honored and humbled to welcome Prof Sir Mene Pangalos to our Board of Directors and Scientific Advisory Board.

Mene, a visionary in pharma R&D with a remarkable legacy at AstraZeneca, brings over 25 years of expertise in drug discovery and development. His transformative work has not only revolutionized R&D productivity but also fostered scientific collaborations, leading to significant advancements in drug development.

His appointment comes at a pivotal time as Absci scales its AI-enabled drug creation portfolio. His insights and experience will be invaluable as we continue to integrate AI with drug discovery. With Sir Mene on board, I am more confident than ever in our mission to transform patient care through our innovative AI approaches. Here’s to a future where our combined efforts will bring about groundbreaking changes in the healthcare industry!

Dec 4 · linkedin

I’m excited to announce our partnership with AstraZeneca to bring generative AI Drug Creation to the fight against cancer!

This partnership unites Absci’s innovative AI drug discovery platform with AstraZeneca’s leading oncology expertise. Together, we’re poised to accelerate the discovery and development of a novel AI-designed oncology therapeutic for patients in need.

Thank you to the incredible team that made this happen from AZ and Absci – Puja Sapra, Susan Galbraith, Rebecca Croasdale-Wood, Simon Chell, Laura Ferguson, Gayatri Varma, Andreas Busch, Sarah Korman, Amaro Taylor-Weiner, Beverly Crider, PhD, CA-AM, and Amir S..

Related Questions

What are some of the key milestones achieved by AbSci under Sean McClain's leadership?
How did Sean McClain's background in molecular and cellular biology influence his approach to founding AbSci?
What innovative technologies has AbSci developed under Sean McClain's guidance?
How has AbSci's valuation changed since its founding in 2011?
What are the main areas of therapy that AbSci focuses on with its protein and antibody products?
Sean McClain
Sean McClain, photo 1
Sean McClain, photo 2
Add to my network

Location

Portland, Oregon